A phase 3 trial evaluating an investigational therapy for the treatment of pantothenate kinase-associated neurodegeneration did not meet its primary or secondary end points.
The FDA has approved Xeomin (incobotulinumtoxinA; Merz) as a first-line treatment for blepharospasm in adults.
Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.
The use of somatosensory temporal discrimination testing did not incite any changes in the mean velocity of index finger movements in either patients with dystonia or healthy controls.
Children with a complex motor disorder, characterized by a combination of movement and posture abnormalities (eg, spasticity and dystonia), were enrolled.
Researchers collected and analyzed data on age at onset, sex, family history of dystonia, and the presence of associated anatomic sites with dystonia.
Although treatment with botulinum toxin is effective for pain and posturing associated with cervical dystonia, myoclonus and tremor remain difficult to treat and contribute to compromised quality of life for patients with this movement disorder.
There is speculation that dystonia is the result of dysfunction occurring in either the cerebellum or basal ganglia or as a result of an abnormal interaction between the two.
Alcohol improves cerebellar-learning deficit in patients with myoclonus-dystonia.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
